Mukund Iyengar, Founder and CEO of Jori, shared a post on X:
“ASCO this year has 5,000+ abstracts.
But maybe 24 will actually change practice. This is that map. (ERRATA: this plot fixes an error on VICTORIA which reflected incorrect data, thanks Rebecca Shatsky.)
Map spans 12 disease areas, 24 critical readouts, 5 plenaries and 2 confirmed misses already on the board.
Few things jump out immediately:
- Pancreatic cancer gets the headline. Daraxonrasib: 13.2 vs 6.7 months.
- Sarcoma gets a plenary because public science funded what pharma would not.
- Lung cancer remains the most crowded battlefield in oncology: RET adjuvant, bispecific OS, post-osimertinib, next-gen EGFR.
By next week, some of these cells will become new standards of care.
This is your cheat sheet to keep score in real time.”
Other articles featuring Mukund Iyengar on OncoDaily.